Merck & Company Inc (MRK)vsPrecipio Inc (PRPO)
MRK
Merck & Company Inc
$144.70
-2.49%
HEALTHCARE · Cap: $368.89B
PRPO
Precipio Inc
$18.62
+4.67%
HEALTHCARE · Cap: $35.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 247631% more annual revenue ($67.38B vs $27.20M). MRK leads profitability with a 3.6% profit margin vs -4.5%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
PRPO
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$144.70
$60.04 premium
Intrinsic value data unavailable for PRPO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 24.2% year-over-year
Areas to Watch
Trading at 8.5x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PRPO
The strongest argument for PRPO centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 24.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PRPO
The primary concerns for PRPO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while PRPO is a growth play — different risk/reward profiles.
PRPO carries more volatility with a beta of 1.30 — expect wider price swings.
PRPO is growing revenue faster at 24.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Precipio Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?